Introduction
Reports of improvement in organ function (including kidney) in animals with erythropoiesis-stimulating agent (ESA) treatment following various interventions [1, 2] suggested that ESAs may have broad effects. This formed the basis for clinical studies to examine a 'tissue-protective' effect of ESAs and potentially offered a mechanistic explanation for some observations in certain clinical studies with ESAs [2, 3] .
The hypothesis that ESAs have direct effects on nonerythroid cells was spawned by reports that renal and other tissues express EpoR messenger RNA (mRNA) and/or EpoR protein and that ESAs induced signaling and other biological effects in cultured renal cells and cell lines [1] . However, detection of EpoR mRNA transcripts was primarily by non-quantitative reverse transcriptionpolymerase chain reaction (RT-PCR) methodologies [1, 2] and lacked appropriate positive controls. Furthermore, it was not possible to demonstrate that EpoR transcripts were translated into EpoR protein because of the poor specificity and sensitivity of the available anti-EpoR antibodies [4] [5] [6] . The lack of such antibodies has been a substantial impediment to the field. In a recent study, no ESA-induced intracellular signaling was detected nor were tissue-protective effects observed in vitro with cardiomyocytes or renal proximal tubule or endothelial cells [7] . In keeping with these findings, and in contrast to the animal studies, multiple human clinical studies showed no improvement in renal function with ESA treatment following transplant [8] [9] [10] [11] [12] [13] or acute kidney injury [14] .
Recently, a sensitive and specific anti-human EpoR antibody suitable for western immunoblotting was described (A82) [15] and EpoR-positive and EpoR-negative control cell types were identified and validated [7, 16] . According to results with these reagents, EpoR protein expression was found to be low to undetectable in tissues and cell lines derived from endothelium, kidney, brain and heart [7, 16] . Furthermore, there was no response to rHuEpo detected in controlled experiments in endothelial, cardiac and renal proximal tubule epithelial cells (RPTECs) [7] questioning the validity of a direct ESA effect on non-hematopoietic cells.
In this study, and in contrast to that observed with EpoR transcripts [7, 17] and immunohistochemistry results with non-specific anti-EpoR antibodies [18] , we further show with A82 that EpoR protein expression is not widely expressed with minimal levels detected in panels of human and mouse tissues and cell types that included renal cells. In addition, there was no Epo-dependent function observed in renal cells; renal cell lines showed no intracellular signaling, primary renal cells did not proliferate with rHuEpo nor was rHuEpo protective against cytotoxic injury. These results call into question the hypothesis that cells from renal tissues, and other nonhematopoietic tissues, express functional EpoR.
Methods

Cells, cell lines and cell culture
Cell lines were obtained from a variety of sources including the American Type Culture Collection (ATCC, Manassas, VA), European Collection of Cell Cultures (Salisbury, UK) and the German Collection of Microorganisms and Cell Culture (Braunschweig, Germany). EpoR-positive control cell lines UT-7/Epo [19] and OCIM-1 [20] were generous gifts from Dr N. Komatsu (Jichi Medical School, Minamikawachi, Japan) and Dr V. Broudy (University of Washington, Seattle, WI), respectively. UT-7/GM-CSF is a subline of UT-7/Epo made by selection for growth in medium containing GM-CSF and lacking rHuEpo. Cell lines were grown in media as recommended or as described previously [7, 16] . Epo-dependent cell lines were supplemented with 1 U/mL rHuEpo (Amgen Inc., Thousand Oaks, CA).
Renal cell lines used are shown in Table 1 . RPT-Myc-BclXL was constructed from renal proximal tubule cells (Lonza, Walkerville, MD) as described [21] . Human renal epithelial cells (HRE), human renal cortical epithelial (HRCE) cells, RPTECs and normal human mesangial cells (NHMC) were cultured according to the supplier's instructions (Lonza). Purified cells expressing CD36 + were cultured as instructed by the supplier (Stemcell Technologies, Vancouver, Canada). Erythroid progenitor cells were generated from peripheral blood CD34 + cells (Stemcell Technologies) by culturing in StemSpan Serum Free media (Stemcell Technologies) containing 50 ng/mL SCF (R&D Systems, Minneapolis, MN), 10 ng/mL IL-3 (R&D Systems), 10 ng/mL IL-6 (R&D Systems) and 5 U/mL rHuEpo (Amgen Inc.). After 6 days of culture, there were primarily erythroid cells according to flow cytometry (BD LSR II flow cytometer; BD Biosciences, Burlington, MA) with specific antibodies (Table 2 ) [15] .
Preparation of mouse and human tissues
Human tissue samples were from Zoion (Zoion Diagnostics, Hawthorne, NY) and the National Resource Center (Bethesda, MD). Mouse tissues were harvested from wild-type (WT; C57/Bl6) or homozygous Human EPOR knock-in (KI) mice [22] (kindly provided by J. Prchal; University of Utah, Salt Lake City, UT). Mice were injected subcutaneously with either carrier [0.1% bovine serum albumin (BSA) in phosphate-buffered saline] or with 1 mg/kg (0.2 mL) recombinant mouse Epo (rMsEpo; Amgen Inc.) to induce an erythroid response and sacrificed for tissue collection on Day 4. Tissues, primary cells and cell lines were homogenized in ice-cold buffer containing 50 mM Tris-HCl pH 7.2, 150 mM 
293T
Normal kidney (SV40 transformed) NaCl, 1% Triton X-100, 0.1% sodium deoxycholate, Complete Protease Inhibitor Cocktail (Roche Diagnostics, Indianapolis, IN), 100 μg/mL Pefabloc-SC (Roche Diagnostics) and 10 μg/mL pepstatin (Roche Diagnostics). Samples were then incubated for 30 min on ice, sonicated and stored at −80°C. Cell preparations examined in western blots were prepared by adding 1× reducing agent (Invitrogen, Carlsbad, CA) and 1× LDS buffer (Invitrogen) and boiling the sample for 10 min.
EpoR western immunoblotting
Samples containing 15-20 μg protein, equivalent to ∼80 000 to 120 000 cells, were loaded on gels and EpoR western blots were prepared. Blots were probed with a rabbit monoclonal antibody (mAb) specific to human EpoR (A82) as described previously [15, 16] . For loading controls, the membranes were stripped and probed with anti-cyclophilin B, (ab106045; Abcam, Cambridge, MA) or proteins were detected directly with the Criterion Stain Free Gel imaging system (BioRad Inc., Hercules, CA) or by staining with Coomassie blue. Secondary antibodies were horseradish peroxidase-linked anti-rabbit IgGs (HRP-IgG; Jackson Laboratories, Bar Harbor, ME) used at 10 ng/mL. EpoR protein levels were estimated using semi-quantitative western blots by comparing band intensity of purified EpoR extracellular domain to the 59-kDa full-length protein in the cell lysate of interest as described previously [16] .
EpoR, Jak2 and Plk1 knockdown
Transcript levels of target genes were diminished in various cells (Table 3 ) by siRNA knockdown following transient transfections. Viability was measured on a luminometer using Cell Titer Glo (Promega, Madison, WI) after 4-5 days as described previously [16] . In each cell line, eight small inhibitory RNAs (siRNAs) targeting janus kinase 2 (Jak2), EpoR, or polo-like kinase 1 (Plk1) ( Table 1) were tested along with >11 000 siRNAs targeting a total of >1300 genes. Data were processed through Screener® (Genedata, Basel, Switzerland). The siRNAs were shown previously to decrease EpoR [16] and Jak 2 (Swift and Kassner, unpublished work) protein levels in positive control cells. The effect of each siRNA on cellular viability was normalized to negative controls on the same plate to generate a percentage of negative control (POC) value. A gene-based P-value was derived from POC values for the siRNAs directed against a given gene compared to siRNAs against all other genes in the screen using a one-tailed Mantel-Cox log-rank test; a rank-based method that can be performed either by ranking siRNAs by POC in ascending or descending order. P-values using both methods were calculated, the lowest P-value was then chosen and converted to a true P-value using a simulation to account for the multiple Pvalue methods employed and their covariance. P-values were then used to calculate a false discovery rate (FDR) by the Benjamini-Hochberg method.
Detection of cell-surface EpoR on intact cells
Cell-surface EpoR was determined on intact cells using competitive binding with [
125 I]-rHuEpo (GE Healthcare, Buckinghamshire, UK) using versene (EDTA/EGTA) to dislodge them from plates as described previously [7] . Specific binding was non-specific binding ([ 125 I]-rHuEpo + excess cold rHuEpo) subtracted from total binding.
Binding of anti-EpoR antibodies to the surface of intact cells was performed on viable cells and flow cytometry, as described previously [15] . Primary antibodies were rabbit anti-EpoR mAb (A82; 1.25 μg/mL) or rabbit IgG1 isotype control mAb (1.25 μg/mL; Cell Signaling Technology, Danvers, MA). Primary antibody binding was detected with a goat anti-rabbit IgG (Fc specific) Alexa Fluor® 488-labeled secondary antibody (Cell Signaling Technology). Phycoerythrin (PE)-conjugated antiEpoR antibody (MAB 307; R&D Systems) or PE-conjugated mouse IgG2b matched isotype control antibody were also used as recommended by the manufacturer. Prior to fluorescence activated cell sorting (FACS) analysis (LSR II flow cytometer), all samples were stained with 5 μg/mL 7-amino-actinomycin-D (Invitrogen) to allow for exclusion of dead/ apoptotic cells. Mean fluorescence intensity was determined and data were expressed as fold change above isotype values.
Cell signaling studies
In order to maximize sensitivity to rHuEpo, cells were serum and rHuEpo starved in basal media for 5 h. Similarly, UT-7/Epo were starved in basal media lacking rHuEpo but containing 1% FBS. Cells were incubated with buffer, 5 U/mL rHuEpo or an EGF/HGF/IGF-1 cocktail [EGF (100 ng/mL; Roche), HGF (500 ng/mL; R&D Systems) and IGF-1 (500 ng/mL; R&D Systems)]. Treated cells were lysed in buffer containing 10 mM sodium fluoride and 10 mM sodium orthovanadate. For STAT5 phosphorylation studies, lysates were immunoprecipitated with either anti-STAT5A (ab12195; Abcam) or anti-STAT5B (ab65743; Abcam) antibodies and westerns were probed with either anti-phosphorylated STAT5A/B (KAPTF015; Stressgen, Plymouth Meeting, PA) or anti-STAT5A/B (ab16276; Abcam). AKT phosphorylation was detected with anti-phosphorylated AKT (9271L; Cell Signaling Technology) and total amounts with anti-AKT (9272; Cell Signaling Technology).
In flow cytometry signaling experiments, serum-starved cells were stimulated for 5 and 30 min with vehicle (rHuEpo formulation buffer), rHuEpo or the EGF/HGF/IGF-1 cocktail and processed as described previously [16] . Cells were then stained for 1 h at room temperature with fluorochrome-conjugated antibodies that are specific for the phosphorylated forms of AKT (Alexa Fluor 647; Cell Signaling Technology), ERK1/2 (Alexa Fluor 647; Cell Signaling Technology), S6 Ribosomal Protein (S6RP; Alexa Fluor 488; Cell Signaling Technology) and STAT5 (Alexa Fluor 488; BD Biosciences)] run on a FACS instrument (LSRII, BD Biosciences) and analyzed using FACSDiva software (BD Biosciences). Results are reported as fold change compared to vehicle treatment alone. Experiments were performed three times for each cell line. 
Cell proliferation and viability studies
Early passage RPTECs (less than four passages) were plated at 6.7 x 10 3 cells/cm 2 in REGM (Lonza), which contains 0.5% FBS and with 10 ng/ mL EGF, 10 U/mL rHuEpo or no growth factor. After 15 h, three flasks for each condition were harvested using trypsin and viable cells were counted by a Vi-cell XR cell viability analyzer (Beckman Coulter, Fullerton, CA). Control cells included Epo-dependent UT-7/Epo and Epo non-responsive OCIM-1 cells. These control cells were suspended at 50 000 cells/mL in the recommended medium containing 10% FBS with or without rHuEpo in triplicate flasks for each time point and viable cells were counted. The effect of rHuEpo on viability of renal cells treated with cisplatin was performed on early passage RPTECs and NHMCs. Cell survival was assessed using a Vialight cell viability assay (Lonza). Statistical analysis was by both Kruskal-Wallis and unpaired t-tests (Graphpad Prism 5).
Results
There was no effect of EpoR knockdown on viability of non-hematopoietic cells
We sought to determine if EpoR or its immediate essential downstream signaling protein (Jak2) was required for survival of human non-hematopoietic cells. The strategy was to diminish EpoR and Jak2 transcript levels through knockdown with a panel of eight specific siRNAs for each gene using cell lines selected from various tissue sources including kidney (Table 3) . SiRNAs to Plk1, that is known to be required for survival of most cell types served as a positive control [16] . We also included a positive control cell line (UT-7/Epo) known to be dependent on Epo, EpoR and Jak2 for survival. To assess the effect of knockdown by the panel of siRNAs in each screen, a statistical method (FDR, see Methods) was used to calculate the probability of an expected false-positive effect. As shown in Figure 1 , viability of nearly all the cell lines was significantly impaired by knockdown of Plk1 (FDR <0.05), and there was reduced viability of UT-7/Epo cells following siRNA knockdown of EpoR (FDR <0.00001). There was little effect of EpoR knockdown on any of the other 16 cell lines tested, which included a negative control cell line (UT-7/GM-CSF) and two renal lines (293T and RPTMyc-BclXl). Knockdown of Jak2 significantly affected viability of only 2 of 37 different lines tested, UT-7/Epo (FDR <0.00001) and in one of two experiments with HCC70 (FDR = 0.027 and 0.23), the latter being derived from a primary ductal carcinoma of the breast. A subclone of the parental line UT-7 that was conditioned for growth in GM-CSF (UT-7/GM-CSF [16] ) was also modestly sensitive to knockdown of Jak2 (FDR = 0.054). The relatively modest effect of Jak2 knockdown in UT-7/GM-CSF was unexpected given that Jak2 is thought to be critical for downstream signaling through GM-CSFR. The dissimilar effects of knockdown of Jak2 with UT-7/Epo versus UT-7/GM-CSF was also surprising and may reflect different growth characteristics and/or kinetics of cell death of the two cell lines. Alternatively, UT-7/GM-CSF cells might have undergone additional genetic changes that allow other molecules to fulfill similar roles as Jak2.
The biological significance for the sensitivity of HCC70 to knockdown of Jak2 in one experiment is also unknown. Furthermore, it is unlikely to involve EpoR since siRNAs to EpoR did not affect viability of this cell line. However, consistent with a genuine Jak2 effect is Jak2's known role to signal for other receptors, e.g. prolactinR [23] . Overall, the lack of effect of Jak2 knockdown in multiple cell lines excluded an important role for the EpoR/Jak2 in those cells. Notably, there was no effect of Jak2 knockdown on viability of four different renal cell lines nor an effect on viability of human umbilical vein endothelial cells (HUVEC). This suggests that neither EpoR nor the EpoR signaling pathway are important for survival of non-hematopoietic cell lines.
Expression profiling of EpoR
To assess EpoR protein expression in cells and tissues, EpoR western blots were probed with the specific and sensitive anti-human EpoR rabbit monoclonal antibody (A82) [15] . This antibody detected as little as 150 fg EpoR by western under optimal conditions [15] . Conservatively, we estimated that the limit of detection with this assay was <100 dimers/cell. It is important to note that western blots detect total EpoR (surface and intracellular) Fig. 1 . Lack of effect with siRNAs targeting EpoR and Jak2 suggests that they are not essential for viability of cell lines. High-throughput siRNA assays measuring cell viability 4-5 days after transfection were conducted in the panel of cell lines (Table 3 ) using eight different siRNAs per gene for each screen (Table 4) . Most cell lines were examined in at least two independent screens. FDR calculated for multiple siRNAs targeting genes for EpoR (A), Jak2 (B) and Plk1(C) are plotted for each screen. Each symbol represents the FDR from one screen with each cell line. The action of Plk1 siRNAs served as a positive control in these experiments and when multiple screens on the same cell line were performed, the EpoR/Jak2 FDR from the screen showing the lowest FDR for Plk1 is shown. The dotted line indicates an FDR of 0.05. Normal cell types were human primary cells from nontumor tissues (Table 3) . Cell lines showing significant sensitivity to siRNAs targeting EpoR or Jak2 or lack of sensitivity to Plk1 are indicated. Data for UT-7/Epo, UT-7/GM-CSF, A2780 and NCI-H1299 have been previously reported [16] .
but <10% of total EpoR protein finds its way to the cell surface [16, 24, 25] .
As reported previously, there were no bands detected in renal 769-P cells (Figure 2A ) [15, 16] . In contrast, the EpoR, which migrates at 59 kDa [4, 15] , was evident in OCIM-1 cells, an erythroleukemia cell line known to express EpoR protein at levels comparable to erythroid progenitor cells [15, 16, 20] . EpoR proteins are subject to intracellular degradation which likely accounts for the smaller EpoR fragments detected in these extracts [15] . As an additional positive control for EpoR protein expression, we wanted to use a cell population that was more reflective of the normal situation compared with the immortalized cell lines. We therefore used normal erythroid cells because they are known to be responsive to Epo and express functionally relevant levels of EpoR. Unfractionated bone marrow (BM) cells (liquid fraction) were largely negative for EpoR (Lane 3). This is likely because erythroid cells represent a small proportion in the liquid fraction of the total BM [26] [27] [28] and non-erythroid BM cells do not express EpoR. Consistent with this, EpoR was not detected in BM and other non-erythroid cell types according to rHuEpo binding studies [27, 29] and hybridization experiments with EpoR probes [30] . CD36 + (glycoprotein IIIb) is a surface marker expressed on erythroid cells but also on some other cell types including megakaryocytes and monocytes [31] . CD36 Table 2 , by Day 6, most of the cells in the population were positive for erythroid markers (CD36 and CD71), while low for markers of other hematopoietic lineages (CD4, CD8, CD14, CD15, CD33, CD34 and CD38). Figure 2B shows an anti-EpoR western with a panel of human tissues probed with the A82 antibody. In this experiment, a 59-kDa EpoR was apparent with the cultured erythroid cells but no 59-kDa EpoR was detected in any other tissue including kidney. According to semi-quantitative immunoblotting, we estimated that the erythroid cells had a total of 8000-16 000 EpoR dimers/cell.
EpoR protein expression in mouse tissues was examined because many experiments that reported non-hematopoietic benefit of ESAs were performed in rodents. However, the A82 antibody used above is specific to human EpoR and we could not identify suitable anti-EpoR antibodies to detect murine EpoR. To overcome this, a KI mouse [22] was employed whereby human EPOR coding sequences replaced the murine EPOR coding region by homologous recombination. With this construct, the human EPOR gene remained under control of the murine Fig. 2 . EpoR is detected in CD34+ cells induced to differentiate to erythroid cells but is low in other cell types including renal cells. EpoR was detected by anti-human EpoR mAb A82 western immunoblot (IB) analysis of cell lysates. Position of the molecular weight markers and the 59-kDa full-length EpoR is indicated (arrow). The smaller proteins detected with A82 were confirmed by Mass-Spec analysis to be EpoR fragments [15] . Levels of these fragments increase when cells are grown with rHuEpo and are observed with long exposures with samples that express lower levels of EpoR. A faint band slightly >60 kDa is sometimes observed in EpoR-positive cells. Its appearance is variable and may represent an incompletely denatured/reduced form of EpoR. (A) CD34 + cells purified from peripheral blood were cultured under conditions where they differentiated into erythroid cells. Samples from the indicated days are shown. Maximal EpoR expression was detected after ∼4 days of culture. These cells were nucleated, visually uniform and had erythroblast characteristics. By Day 8-10, cell pellets had red coloring consistent with hemoglobin accumulation. (B) EpoR expression in human tissues. Human tissues were prepared as described in Methods. CD34
+ cells cultured for 6 days were used as a positive control. Twenty micrograms of each lysate was loaded in each lane, which corresponds to ∼120 000 cells. Proteins on the gel were detected using the Criterion Stain Free Gel imaging system (BioRad Inc.). An image of a section of the gel is shown. The 59-kDa full-length EpoR is indicated (arrow).
EPOR gene regulatory regions. The homozygous KI mice had similar EpoR transcript levels in bone marrow as WT mice but were slightly anemic (Hct was ∼45 versus 49), had smaller spleens (∼20% decreased weight) but grew normally with no other organ abnormalities [22] . Tissues from WT mice served as negative controls. A positive control for this experiment was spleen tissue harvested from KI mice that had been treated with rMsEpo. rMsEpo was deliberately used because it activates human EpoR and because it was also used in WT mice where we wanted to maximize the erythroid response. Mouse spleens are enriched for EpoR-positive erythroid cells because of the extensive extra-medullary erythropoiesis that occurs in spleen following ESA administration. The treated human EpoR KI mice showed a robust erythroid response to rMsEpo with enlarged spleens. The EpoR-specific bands were observed in the spleens from KI mice treated with rMsEpo with levels comparable to that seen in human erythroid progenitor cells ( Figure 3A) . There was also a small amount of 59-kDa EpoR detected in spleen tissue from untreated KI mice but not WT mice. This latter result was as expected given the inability of the A82 antibody to detect murine EpoR protein.
In contrast to KI mouse spleen, but consistent with the analysis of human tissues, 59-kDa EpoR was not detected in any other KI tissue including kidney ( Figure 3B ). With some KI tissues, e.g. ovary and lymph node, proteins that migrated lower on the gels than the 59-kDa EpoR were detected. These bands were also detected in the corresponding WT (negative control) mouse tissues (data not shown). This suggested that these bands were non-EpoR proteins that cross-reacted with the A82 antibody.
To examine EpoR expression in renal cells in more detail, primary human renal cells and renal cell lines (Table 1) were examined. SK-NEP-1 cells were also included because they were initially reported to be from a Wilm's tumor (nephroblastoma); however, later genetic characterization suggested that they were more likely from a Ewing's sarcoma [32] . They were also of interest because EpoR protein was detected in these cells (see below).
EpoR mRNA transcripts were detected by quantitative RT-PCR in the renal cell lines but levels were 10-to 1000-fold lower than in the positive control (UT-7/Epo) (Supplementary Figure 1) . In western blots, faint but clear staining of 59-kDa EpoR was detected in some populations of the human primary renal cell preparations (Figure 4 ). According to semi-quantitative immunoblotting, levels were ∼40 to 80 dimers/cell. Similar to the primary cell preparations from kidney, only faint staining of 59-kDA EpoR was detected in some renal cell lines comparable to levels in the primary renal cells.
EpoR was not detected on the surface of renal cells
As noted above, very low levels of EpoR were detected in some renal cell types. To determine if any of this EpoR protein could be detected on the cell surface, competitive binding experiments with [ bound decreased with increasing amounts of cold competitor rHuEpo. These cells express ∼10 000-20 000 surface receptors with a Kd of 90 pM according to Scatchard analysis. In contrast, no specific cell surface binding was detected with the renal cells that were examined (769-P, RPTEC, HRCE, NHMC; Figure 5A and B). The limit of detection with this assay is ∼100 EpoR per cell [16] .
To examine EpoR expression at the single-cell level, we used anti-EpoR flow cytometry with two different antibody preparations, A82 and MAB307. A82 was shown previously to specifically detect EpoR on cell lines expressing low levels on their cell surface [15, 16] . MAB307 appears to detect a conformational epitope that renders the antibody unsuitable for western blotting but it bound specifically to the surface of EpoR-positive but not EpoR-negative control cell lines with a similar degree of sensitivity as A82 (data not shown). Consistent with the binding data, specific binding of both antibodies was detected with EpoR-positive (UT-7/Epo) but not EpoRnegative control cells (HT-29), 769-P cells nor RPTECs ( Figure 5C ). In addition, there were no sub-populations of RPTEC cells with elevated levels of anti-EpoR antibody binding in this experiment (data not shown). Similarly, no anti-EpoR antibody binding was detected on SK-NEP-1 cells (Supplementary Figure 2) .
No EpoR activation in renal Cell lines by rHuEpo
The results presented thus far suggest that there were very low levels of EpoR protein expression in renal cells. However, it was possible that this low-level receptor expression was of biological significance. Alternatively, it has been postulated that ESAs may signal through an alternate receptor complex that involved the GM-CSF beta common receptor. To address these possibilities, signaling studies (increased phosphorylation of proteins known to be a part of the intracellular signaling network) with rHuEpo were performed. Because this method is more sensitive than binding studies and makes no assumptions about the nature of the EpoR on cells, activation of cells with low levels of EpoR would be detected. HK-2 and SK-NEP-1 cells were examined because they expressed the highest relative levels of EpoR protein (Figure 4) . Positive controls were UT-7/Epo and Day 6 erythroid progenitors. COLO677 cells were the negative control. OCIM-1 cells were included as an additional control because despite relatively high-level expression of total [15, 16] and surface [15, 20] EpoR, they are not responsive to rHuEpo [20] . Two approaches were used to examine phosphorylated proteins, western blotting and binding of phospho-specific fluorochrome-conjugated antibodies assessed by flow cytometry. By western analysis, rHuEpo addition readily induced phosphorylation of STAT5A, STAT5B and AKT in the positive control cells with no effect on COLO677 cells ( Figure 6A ). OCIM-1 cells had constitutive phosphorylation of pSTAT5A and pSTAT5B in starved cells that was not increased significantly with rHuEpo and no phosphorylation of AKT with (or without) rHuEpo. With 769-P cells, there was constitutive phosphorylation of STAT5B and AKT in starved cells that was not increased with rHuEpo ( Figure 6B) . Similarly, rHuEpo did not increase levels of pAKT, pSTAT5A or pSTAT5B in SK-NEP-1 or HK-2 cells. In control experiments with the renal lines, a growth factor + cells (erythroid cells). The position of the 59-kDa full-length EpoR protein is indicated by the arrow. Note that SK-NEP1 cells, although initially thought to be a nephroblastoma likely, is actually an Ewing's sarcoma. We estimated that EpoR levels in SK-NEP1 cells was ∼400 to 800 EpoR dimers/cell. cocktail (EGF/HGF/IGF-1) induced phosphorylation of AKT but not STAT5 ( Figure 6B ) indicating that growth factor responses could be detected in these cells.
In UT-7/Epo cells, rHuEpo also induced dose-dependent increases in phosphorylation of STAT5 after rHuEpo addition (30 min of stimulation) when examined by flow cytometry, but no increased phosphorylation could be detected at any rHuEpo concentration with the negative control (HT-29), renal (769-P) or SK-NEP-1 cells (Supplementary Figure 3) . Similarly, no increase in pAKT, pERK, pS6RP or phospho-serine on STAT3 was seen with 769-P, SK-NEP-1 cells stimulated for either 5 or 30 min with rHuEpo (data not shown).
No effect of rHuEpo on growth or viability of renal cells invitro
Although we were unable to detect evidence of intracellular signaling by rHuEpo, we further sought to determine if there was any biological effect on primary renal epithelial cells. Again, these experiments make no assumptions regarding the EpoR-signaling complex. To this end proliferation studies were employed. As shown in Figure 7A , positive control UT-7/Epo cells showed a rHuEpo-dependent increase in growth. In agreement with Fig. 7 . No effect of rHuEpo on growth or survival of renal cells. RPTECs derived from primary tissue were plated after the second passage at low density with either 10 U/mL rHuEpo, 10 ng/mL EGF or no growth factors (G.F.). Viable cells were counted 15 h after plating and daily for 4 days and then again at Day 7 and 8. Results are from one experiment; two other experiments yielded equivalent results. (A) Positive control cell line UT-7/ Epo grown with the indicated amounts of rHuEpo showed dose-dependent increases in cell number with increasing amounts of rHuEpo. The 1 U/mL and 10 U/mL curves were identical; 0.1 U/mL and 10 U/mL curves are shown. (B) OCIM-1 cells express EpoR protein on their cell surface but they are not responsive to Epo [20] and therefore served as a negative control for growth. OCIM-1 cells showed no effect on cell density at any dose of rHuEpo (0.1, 1.0, 10 U/mL), the highest Epo concentration tested is shown (10 U/mL). (C) RPTECs grown in medium containing 0.5% serum and insulin, or the same medium with EGF or rHuEpo. There was no increase in growth, above the no growth factor control, at any rHuEpo concentration tested (0.1, 1.0, 10 U/mL). The highest concentration tested (10 U/mL) is shown. The error bars in each experiment represent the SEM for triplicate flasks at each time point (A-C). (D) Primary human kidney mesangial cells or (E) primary human RPTECs were pre-treated with 10 U/mL rHuEpo or with medium alone for 24 h before the addition of cisplatin at a final concentration of 20 and 30 μM. The control groups were pre-treatment with rHuEpo or medium alone without cisplatin treatment (no drug). Survival was measured after 48 h of cisplatin treatment. Mean ± SD are shown (n = 16 per group).
constitutive activation and lack of increased phosphorylation of intracellular signaling molecules with rHuEpo, OCIM-1 cells grew without rHuEpo and showed no enhanced growth with rHuEpo at any concentration up to10 U/mL. Data for the highest concentration, 10 U/mL, are shown in Figure 7B . In medium containing insulin and low levels of serum, RPTECs grew slowly but faster in the presence of a positive control growth factor (EGF; Figure 7C ) and reached a higher cell density before they displayed contact inhibition, indicating that these cells can proliferate faster with some growth factors. In contrast to the effect seen with EGF, there was no increase in proliferation with any concentration of rHuEpo tested compared to the media-alone control (experiment performed three times). Similarly, there was no difference in relative viability of RPTECs with or without rHuEpo as measured by trypan blue exclusion (data not shown). To enhance the sensitivity of this assay and to see if the lack of response to Epo was due to inhibitory cytokines present in serum, the experiment was also performed in medium lacking serum, insulin and growth factors. In this minimal medium, RPTECs did not proliferate with or without 10 U/mL rHuEpo, but addition of EGF increased growth (∼4-fold increase in cell number over 8 days; data not shown).
While rHuEpo had no effect on proliferation of RPTECs, we performed additional experiments to establish if rHuEpo could improve viability after cytotoxic injury through reduced apoptosis. Cisplatin treatment was used because it was reported to increase apoptosis (caspase activity) and reduce viability in earlier ESA protection studies with RPTECs [7] . Human renal cells were treated for 24 h with either 10 U/mL rHuEpo or medium alone followed by 48 h of treatment with the cytotoxic agent cisplatin. As shown in Figure 7D and E, cisplatin reduced viability of both RPTECs and NHMCs (P < 0.0001) but pre-treatment with rHuEpo followed by cisplatin did not result in a statistically significant difference in the viability of either RPTECs or NHMCs.
Discussion
In this study, we measured EpoR mRNA and protein levels and inhibited EpoR function with siRNAs and examined if rHuEpo could have a direct effect on renal cells and cell lines through activation of EpoR resident on their surface. According to these data, EpoR protein was detected in positive control cell types but was low to undetectable in non-hematopoietic tissues including kidney. EpoR mRNA and protein levels were also relatively low in primary renal cells and cell lines and EpoR was not detectable on their cell surface. The increased EpoR protein detected in the mouse spleen with Epo treatment is likely due to increased numbers of EpoR erythroid progenitor cells and not EpoR upregulation by Epo. In support of the latter, EpoR did not increase with Epo treatment in Epo-deficient skeletal muscles [33] , in endothelial cells grown with Epo [34] and EpoR increased in differentiating erythroid cells in the absence of Epo (Busse and Elliott, unpublished work). In other experiments, rHuEpo neither induced intracellular signaling of renal cell lines nor affected growth of RPTECs or viability of RPTECs or NHMCs treated with cisplatin in vitro. In other controlled studies, EpoR mRNA levels in renal and other non-hematopoietic cells were also relatively low [7, 17, 35, 36] , consistent with the ubiquitous basal-level EpoR mRNA expression observed here. Also consistent 
Dharmacon AACAACCAAAGUCGAAUAUGA with our results, RPTEC preparations showed no signaling with rHuEpo nor protection from injury in vitro with darbepoetin alfa when administered either prior to, or simultaneous with, cytotoxic injury [7] . Renal carcinoma cell lines showed no enhanced proliferation with rHuEpo [37] [38] [39] nor did 786-O renal carcinoma cells show enhanced growth with rHuEpo in animal xenograft experiments [40] . Taken together, these observations suggest that there is lack of functional EpoR in renal cells. In addition to lack of functional EpoR in renal cells, EpoR and Jak2 knockdown had no effect on viability of renal and other non-hematopoietic cell lines, suggesting that their expression was not essential. Supporting this conclusion, a transgenic mouse, where EpoR expression was restricted to erythroid cells, grew normally and had normal kidneys [41] . These observations are in contrast to several reports that EpoR knockdown affected cell viability in some non-erythroid cell lines [42] [43] [44] [45] [46] . However, those conclusions are controversial because only single siRNAs were used and false-positive effects due to nonspecific siRNA and to toxicity are well recognized. Furthermore, an effect of EpoR knockdown using the same cell lines was not replicated here and elsewhere [16] .
The lack of effect observed in vitro with rHuEpo on renal cells may be due to insufficient levels of EpoR. Consistent with this, the magnitude of response through EpoR is reported to increase with increased expression level [47, 48] . While BFU-E cells have detectable EpoR on their surface and do not grow on Epo alone, they will do so when EpoR levels are increased [49] . However, SH-SY5Y cells were reported to respond to rHuEpo even though they expressed similarly low levels of EpoR [50] . The observation is controversial because an effect of rHuEpo was not observed in two other studies with SH-SY5Y [7, 51] .
Another possibility is that renal cells may not contain the necessary intracellular signaling networks or chaperone proteins required to move EpoR to the cell surface. Consistent with the former, OCIM-1 cells express relatively high levels of surface EpoR but did not show an increase in intracellular signaling or growth stimulation with rHuEpo ( Figures 2, 6 and 7) . A2780 [16] and SK-NEP-1 cells (this study) also show relatively higher levels of EpoR protein and similarly did not show an increase in intracellular signaling with rHuEpo. While some growth factor-dependent cell lines can acquire dependence on rHuEpo with forced overexpression of EpoR [52, 53] , others did not [54] [55] [56] [57] suggesting that the lack of response was not due to limiting EpoR in those cells.
The hypothesis that functional EpoR was present on renal and other cell types (reviewed in Bahlmann and Fliser [1] ) was initially based on non-quantitative detection of EpoR transcripts by RT-PCR and purported EpoR protein detected by western immunoblotting and immunohistochemistry. However, reports of EpoR protein in renal and other cell types were confounded by lack of sensitivity and specificity of the anti-EpoR antibodies employed [4] [5] [6] . The limited use of appropriate controls made it difficult to interpret the reports of positive effects on intracellular signaling, apoptosis or growth. The importance of such controls was illustrated when trivial manipulations such as media change, or presence of BSA, which is used to stabilize rHuEpo preparations and which can contain growth-promoting contaminants [58] , induced ERK phosphorylation and cellular proliferation [59] . The magnitude and timing of these changes were similar to those previously attributed to ESAs in some uncontrolled studies with renal and other non-hematopoietic cells. Such controls are also necessary to detect effects of endotoxin, which can accumulate in non-sterile reagents and has activities similar to those ascribed to ESAs [60] [61] [62] .
Several possibilities might explain the reno-protective effects of ESAs reported in animals [1, 2] but in the absence of a direct effect of EpoR. The tissue-protective effects of ESAs may be indirect effects of ESA treatment such as increased oxygen delivery due to increased red cell concentrations or changes in iron kinetics that reduced oxidative damage [63, 64] . Alternatively, ESAs increased blood flow through ESA-induced angiogenesis or stimulated wound healing through activation of EpoRs on endothelial progenitor cells or stem cells. However, endothelial cell preparations express little total and surface EpoR and do not respond to ESAs in vitro [7] . Similarly, stem cells, mesenchymal cells and myeloid progenitor cells were reported not to express EpoR [65] raising questions about their possible role in reno-protection by ESAs. Another possibility is that ESAs activated alternate receptors such as GM-CSF beta common. The latter data were supported by results with modified rHuEpo derivatives such as carbamylated Epo [66] . This hypothesis is inconsistent with other reports suggesting tissue-protective effects are not mediated through alternate receptors [67] , with studies performed in the GM-CSF beta common knockout animals [68] and with the results presented here. We saw no effect on pERK or pSTAT5 in renal cells with rHuEpo and these proteins are normally phosphorylated with GM-CSF. ESA reno-protection results may also represent false-positive effects. Consistent with this possibility, some groups have been unable demonstrate tissue protection, including reno-protection, with ESAs in several different animal models [64, [69] [70] [71] . In addition, ESA administration has failed to translate into reno-protective clinical benefit in multiple clinical studies [8] [9] [10] [11] [12] [13] [14] . Clearly, these and other hypotheses need to be considered in interpreting current data and any further preclinical and/or clinical studies should be designed, and interpreted, with alternate mechanisms in mind. Supplementary Figures 1, 2 and 3 are available online at http://ndt.oxfordjournals.org/.
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